Stock Track | Hims & Hers Health Soars 9.74% Intraday on FDA Peptide Deregulation and Novo Nordisk Partnership

Stock Track

Apr 17

Hims & Hers Health Inc.'s stock soared 9.74% intraday on Friday, extending a multi-day rally driven by significant regulatory and commercial developments.

The surge follows news that the U.S. Food and Drug Administration plans to remove 12 peptides from its category 2 restricted list, with an advisory committee review scheduled for July. U.S. Health and Human Services Secretary Robert Kennedy Jr. stated these changes could expand regulated access to peptide-based treatments and shift demand away from black markets.

Additionally, Danish pharmaceutical giant Novo Nordisk entered a partnership to sell weight-loss drugs directly on the Hims platform, significantly broadening the company's product reach in the high-demand weight management space. Analyst sentiment also turned more positive, with BofA Securities raising its price target on the stock while maintaining a Neutral rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1176158437"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176158437\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176158437?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176158437","market":"sg","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 9.74% Intraday on FDA Peptide Deregulation and Novo Nordisk Partnership","media":"Stock Track","content":"<p>Hims & Hers Health Inc.'s stock soared 9.74% intraday on Friday, extending a multi-day rally driven by significant regulatory and commercial developments.</p><p>The surge follows news that the U.S. Food and Drug Administration plans to remove 12 peptides from its category 2 restricted list, with an advisory committee review scheduled for July. U.S. Health and Human Services Secretary Robert Kennedy Jr. stated these changes could expand regulated access to peptide-based treatments and shift demand away from black markets.</p><p>Additionally, Danish pharmaceutical giant Novo Nordisk entered a partnership to sell weight-loss drugs directly on the Hims platform, significantly broadening the company's product reach in the high-demand weight management space. Analyst sentiment also turned more positive, with BofA Securities raising its price target on the stock while maintaining a Neutral rating.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 9.74% Intraday on FDA Peptide Deregulation and Novo Nordisk Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 9.74% Intraday on FDA Peptide Deregulation and Novo Nordisk Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-17 21:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc.'s stock soared 9.74% intraday on Friday, extending a multi-day rally driven by significant regulatory and commercial developments.</p><p>The surge follows news that the U.S. Food and Drug Administration plans to remove 12 peptides from its category 2 restricted list, with an advisory committee review scheduled for July. U.S. Health and Human Services Secretary Robert Kennedy Jr. stated these changes could expand regulated access to peptide-based treatments and shift demand away from black markets.</p><p>Additionally, Danish pharmaceutical giant Novo Nordisk entered a partnership to sell weight-loss drugs directly on the Hims platform, significantly broadening the company's product reach in the high-demand weight management space. Analyst sentiment also turned more positive, with BofA Securities raising its price target on the stock while maintaining a Neutral rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1176158437","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176158437","pubTimestamp":1776433596,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc.'s stock soared 9.74% intraday on Friday, extending a multi-day rally driven by significant regulatory and commercial developments.The surge follows news that the U.S. Food and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘中大涨9.74%受FDA多肽放松管制和诺和诺德合作影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc.'s stock soared 9.74% intraday on Friday, extending a multi-day rally driven by significant regulatory and commercial developments.The surge follows news that the U.S. Food and Drug Administration plans to remove 12 peptides from its category 2 restricted list, with an advisory committee review scheduled for July. U.S. Health and Human Services Secretary Robert Kennedy Jr. stated these changes could expand regulated access to peptide-based treatments and shift demand away from black markets.Additionally, Danish pharmaceutical giant Novo Nordisk entered a partnership to sell weight-loss drugs directly on the Hims platform, significantly broadening the company's product reach in the high-demand weight management space. Analyst sentiment also turned more positive, with BofA Securities raising its price target on the stock while maintaining a Neutral rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}